National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
Search
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Levels of Evidence for Human Studies of Cancer Complementary and Alternative Medicine (PDQ®)
Health Professional VersionLast Modified: 10/02/2002



Introduction






Strength of Study Design






Strength of Endpoints Measured







Combined Level of Evidence Score






More Information



Page Options
Print This Page  Print This Page
Print This Document  Print Entire Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

NIH Calendar of Events

Español
NCI Highlights
New Study of Targeted Therapies for Breast Cancer

The Nation's Investment in Cancer Research FY 2009

President's Cancer Panel Annual Report: 2006-2007

Cancer Trends Progress Report: 2007 Update

Past Highlights
HPV Vaccines for Cervical Cancer
Combined Level of Evidence Score

A combined level of evidence score is calculated for each qualifying study—except for Best Case Series—by joining the score for statistical strength of study design with the score for strength of the endpoint(s) measured. Because of their extremely weak study design, Best Case Series are given a score for strength of study design only (i.e., a level of evidence score of 4). The level of evidence scores for the remaining study types range, in decreasing order of strength, from 1iA to 3iiiDiii.

Back to TopBack to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov